News Hub | News Direct

RemSleep Holdings Inc. Provides a Corporate Update and Correction

RemSleep Holdings, Inc.

RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) patients, provides an update on its testing protocol for 510K clearance of its DeltaWave CPAP Mask as well as a correction on previous update on the Cytotoxicity testing. It was previously announced the Cytotoxicity test was restarted due to contamination. That statement was incorrect. The Cytotoxicity test was started significantly later than was originally communicated to RemSleep and was scheduled to be completed mid to late May. The MLA (Mouse Lymphoma Assay) test was the test which experienced the contamination that had to be restarted once the contamination was identified and deemed to potentially compromise test results. The mid to end of May timeline remained valid for testing completion. About a week ago, RemSleep was informed that the MLA test had once again shown signs of contamination towards the end of the test. The test sample was disposed of before RemSleep could determine the source, or origin of the contamination. At that time, rerunning the test would not represent a material shift in the timeframe due to the Cytotoxicity test starting later than what had previously been communicated to the company. This time, due to the second issue of contamination and remaining tests being completed, the sample was isolated and it was determined the contamination was from mold. Due to the nature of the testing, it is extremely difficult to locate the source of mold contamination. Furthermore, due to the nature of mold, it can develop quickly, whereas with this test it was found near the end and may have developed about midway through the test. Both MLA tests were run by a contracted lab through our primary lab partner. This is due to our primary lab not having the equipment to run this specific test. This is one of two tests that were contracted to outside labs. It is critical to note that the remaining tests have all been run through our primary lab and there have been no contamination or handling issues in any other tests in the protocol. As previously noted, RemSleep went through a strict protocol in preparing the DeltaWave samples for this testing which involved preparing them in a clean room, sterile environment. Additional samples have been prepared for retesting and the company has taken an additional step of shrink wrapping the entire sample prior to shipping to ensure no contamination can be derived from the handling during the shipping process. FDA protocol directs the testing lab to test the unit in question directly from the packaging without any modification, cleaning, sterilization, etc. While RemSleep is confident the precursor to the mold development did not come from handling in the sample preparation at the company facility with the prior samples, this additional abundance of caution was taken to further rule out any possible source of contamination while the Deltawave was in company hands. The Deltawave itself has passed all tests with no issues, so at the end of the day we know Deltawave will get past testing, of which there was never any doubt from the beginning. There was significant discussion about the impact the mold contamination had on the actual test results and moving forward with the MLA results for submission despite the contamination. In the end, there is no way to conclusively prove the mold contamination had no material affect (positive or negative) on the test results and the company was advised to rerun the test. While this will once again delay 510K submission, the successful test results minus the contamination issue validates the company’s assertion and/or belief that the DeltaWave is inherently safe due to the materials used. Along those lines, the company wants to iterate in no uncertain terms that all materials used in the design and manufacture of the DeltaWave device are Class VI Medical Grade and these materials are used safely by millions of Americans every day in FDA cleared devices throughout the US. The company has prepared the new samples as noted above and have been shipped to the testing lab, which will be received by the testing lab 6/1/2023. The company has been assured the new test will take priority and will not be put into a que to start on a later date, which happened previously (with the Cytotoxicity test) resulting in an extended timeline. The company is waiting for confirmation on when the test will be started and how long it will take once started. Further, our primary lab is evaluating the handling of the test by the 3 rd party lab to mitigate any chance of further mold contamination on their end. Based on previous notes provided to our primary lab on the original contamination, it is believed that the first test may also have been due to mold due to several similarities. While it is no comfort to the current situation, the company was informed this isn’t an unusual issue with this particular MLA test. “Obviously we are extremely frustrated and disappointed by this second issue of contamination,” stated RemSleep CEO, Tom Wood. “The frustration is exasperated by not being able to ascertain the source or place where the contamination occurred. You do everything as advised in the handling of the sample products and still can’t be 100% sure. We took the additional steps in this latest sample and assume our partner lab will be able to further mitigate any potential issues on the contracted lab’s end and finally get the DeltaWave submitted for 510K clearance. On a positive note, the successful completion of all the remaining tests as well as no negative indications in the MLA test validate what we believed from the start of this very long process: the DeltaWave is safe as well as being effective. We were looking to expound upon the prior notice of RemSleep receiving the design patent for the DeltaWave along with successful completion of all tests. Now that we must repeat the MLA test again, this milestone accomplishment is clearly overshadowed. We are looking at formats for an investor call or interactive Q&A where we can go into more detail about how these events unfolded and answer investor questions. Further, we would like to provide more detail of the significance of the design patent and how it validates that the DeltaWave is truly unique and how the design aspects of the DeltaWave give us the results we have achieved. It is difficult to give depth into these issues in print. Once we get some of these questions on timeline answered, we will follow up with investors on a conference call or some type of interactive Q&A session format. It is frustrating, but shadows are not falling.” Finally, while the retesting timeline is being finalized, it is expected to the original compilation timeframe that was provided will be shortened as much of that work can be performed while the RMA test is being rerun. RemSleep appreciates the ongoing patience and understanding of investors and inherently understands the frustration and concerns of another setback. The company and will follow up accordingly in press releases, on the company Website: www.remsleep.com, and through the company Twitter feed: @RemsleepInc About RemSleep Holdings Inc. RemSleep Holdings Inc. is a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive Sleep Apnea patients. Our focus is primarily designing and manufacturing devices and products for the treatment of Sleep Apnea and other respiratory conditions. With over 30 years of collective experience in CPAP therapy, the RemSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance. We diligently strive for our products to make the difference and improve the condition of those suffering from Sleep Apnea. www.remsleep.com https://twitter.com/RemsleepInc Forward-Looking Statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. No information in this press release should be construed as any indication whatsoever of the Company's future revenues, results of operations or stock price. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation. Investor Relations Contact: Preya Narain info@preya.co Contact Details Preya Narain, Investor Relations info@preya.co Company Website https://remsleep.com/

May 31, 2023 05:08 PM Eastern Daylight Time

News Release

Monogram Orthopaedics developing next generation surgical robot to enhance orthopaedic surgery

Monogram Orthopaedics

Monogram Orthopaedics CEO Ben Sexson joins Natalie Stoberman from the Proactive studios to share how the company is progressing with its development of orthopedic robots in the medical technology industry. Sexson says Monogram's goal is to create a next-generation surgical robot for the operating room, starting with knee surgeries and expanding to other clinical opportunities. He adds the company has been making progress since its founding in 2016 and recently had meetings with the FDA to introduce their technology and discuss the regulatory process. They are working towards FDA approval while also exploring opportunities outside the U.S. to potentially accelerate their time to market. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 31, 2023 01:50 PM Eastern Daylight Time

Video

Being Overweight or Obese Increases Risk of Developing Colorectal Cancer

MarketJar

Maintaining a healthy weight is important for general health, but growing evidence reveals obesity’s role in the development of chronic illnesses and even deadly cancers. Obesity is one of the most frequent chronic illnesses in the United States, with one out of every three adults in the nation being overweight. Excess weight has been linked to several health risks including diabetes, high blood pressure, heart disease and more recently, colorectal cancer. Colorectal cancer is very common, with an estimated 150,000 new instances of colon and rectal cancer (CRC) per year, but the number of cases in young adults have been increasing rapidly over the last 20 years and excess weight may be to blame. According to a new study published in JAMA Network OpenTrusted Source, being overweight or obese during early and middle adulthood increases the risk of developing this common and potentially deadly cancer. The study comprised 135,161 people ranging in age from 55 to 74 and the findings suggest a strong relationship between high body fat, even in young adulthood, and the development of colon cancer later in life. According to renowned physician and scientist Dr. William Li, excess body fat, particularly visceral fat around the organs can cause chronic inflammation, which is a known trigger for cancer development. The findings from the study highlight the importance of prevention and also signal the need for colon cancer screening. The US Preventive Services Task Force advises screening with stool DNA tests once every three years starting at age 45, however some individuals might want to consider testing earlier. In the US, 16.6 million colonoscopies are carried out annually but around one-third of Americans between the ages of 50 and 75 have ever undergone a colon cancer screening. Fortunately, molecular genetics cancer diagnostic company Mainz Biomed (NASDAQ:MYNZ) is working to commercialize its highly effective and simple-to-use at-home colorectal cancer (CRC) detection test ColoAlert in the US. ColoAlert, which is already available in select European markets, is moving swiftly towards FDA approval following the company’s successful completion of the pre-submission process for its PMA pivotal clinical trial. ColoAlert will be tested in the FDA-registered trial "ReconAAsense" to gain commercial approval in the United States. Once approved through a cooperative partner program with regional and national laboratory service providers, the company's business goal is to achieve scalable distribution across the country. Expanding the Reach of Its Early Detection Tests Across Europe Mainz Biomed has also been working to expand the presence of its flagship cancer screening test across European markets by partnering with third-party laboratories for test kit processing instead of the traditional method of operating a single facility. On May 31, the company announced that it has expanded its commercial footprint into Poland through a partnership with TESTDNA, a leading independent laboratory in Poland. According to Digestive Cancers Europe, Poland has a particularly high need for dependable non-invasive screening methods, as only around 20% of patients opt for colonoscopy. With 19,000 new cases annually and approximately 12,000 colorectal cancer-related deaths, the necessity for effective at-home screening tests with early-stage detection is evident. The addressable market in Poland alone accounts for an estimated 21 million patients. In the coming weeks, the two companies will work together to prepare and launch co-marketing activities to ensure successful commercialization in the Polish market. Mainz Biomed has also expanded its reach within corporations following the launch of its corporate health program in Germany through a merger with BGM, a well-established corporate health program that serves employees at 48 of Germany's 50 largest enterprises. On May 24, Mainz Biomed reported preliminary results from its colorectal cancer screening campaign with Zöller-Kipper GmbH via its BGM cooperation. Zöller-Kipper chose ColoAlert for their corporate health program, which comprises approximately 2,500 employees, in April 2023. Employees found the online patient portal to be straightforward to use and comfortable, and they were able to easily access the portal, obtain a kit, and securely receive findings within five days, according to the results. Click on this link to learn more about Mainz Biomed (NASDAQ:MYNZ) and its operations. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Mainz Biomed NV. Market Jar Media Inc. has or expects to receive from Mainz Biomed NV’s Digital Marketing Agency of Record (Native Ads Inc.) eighty nine thousand seven hundred sixty four USD for 12 days (9 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mainz Biomed NV’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed NV’s industry; (b) market opportunity; (c) Mainz Biomed NV’s business plans and strategies; (d) services that Mainz Biomed NV intends to offer; (e) Mainz Biomed NV’s milestone projections and targets; (f) Mainz Biomed NV’s expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed NV’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed NV’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed NV’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed NV’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed NV’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed NV’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed NV to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed NV’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mainz Biomed NV’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed NV’s business operations (e) Mainz Biomed NV may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Mainz Biomed NV undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mainz Biomed NV nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mainz Biomed NV nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed NV or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed NV or such entities and are not necessarily indicative of future performance of Mainz Biomed NV or such entities. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

May 31, 2023 09:30 AM Eastern Daylight Time

Image

Immunic ultimately hoping to "offer patients a new kind of treatment" for multiple sclerosis

Immunic Inc

Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

May 31, 2023 07:42 AM Eastern Daylight Time

Video

News Release

Neuronetics investing in NeuroStar awareness as drug-free treatment alternative for depression

Neuronetics Inc

Neuronetics CEO Keith Sullivan joins Natalie Stoberman from the Proactive newsroom to discuss how its NeuroStar Advanced Therapy is emerging as an alternative for treating depression. Sullivan explains that NeuroStar delivers a magnetic pulse to a specific part of the brain to reduce depression symptoms. With over 5 million successful treatments on nearly 150,000 patients, Sullivan says NeuroStar offers a promising alternative for those who have failed multiple drugs. However, he adds that there is a lack of awareness among patients and psychiatrists and the company intends to address this challenge by investing approximately $14 million in driving awareness within psychiatric practices and beyond. Contact Details Proactive Invesetors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 30, 2023 01:50 PM Eastern Daylight Time

Video

William Shatner and HearingLife Team Up to Spread Awareness about the Importance of Hearing Care in the US

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/CqMCndmTOfg Would it surprise you to know that hearing loss in the U.S. is expected to double to 73M by 2060?* Hearing loss can prevent a life well-lived and cause some to miss out on meaningful connections. Even so, it takes people seven years from the time they suspect they might have hearing loss to the time they seek treatment. But no one should ever feel that hearing loss is something to be ashamed of. Proactive health habits such as hearing care are so important to living a long and healthy life. Hollywood legend and HearingLife spokesperson, William Shatner, has lived a full, adventurous life, from traveling to space to acting on the big screen. But what many might not realize is he is also living with tinnitus! William Shatner has teamed up with the leading hearing care company to spread awareness about the importance of hearing care in the US. To stress the importance of proper hearing care, HearingLife is currently running its “Love Your Ears” give back campaign and is giving away free hearing aids to people in financial need who are struggling with hearing loss. For the opportunity to receive free hearing aids through “Love Your Ears,” anyone in the U.S. can submit their personal story to www.hearinglife.com/giveback, or nominate a loved one, explaining how receiving hearing aids could make a difference in the quality of their life. HearingLife offers brands with some of the highest rated technology on the market, including several award-winning options. Hearing aid technology has come such a long way to cater to the unique treatment needs of the individual. With so many options out there, it’s crucial for people to seek out professional care from an audiologist or licensed hearing aid specialist. HearingLife offers personalized care with a focus on the individual’s unique needs so that we can provide people with the most optimal solution for their lifestyle. HearingLife.com has plenty of resources available. For more information on the give back program to submit your story, go to www.hearinglife.com/giveback. *Source: https://jamanetwork.com/journals/jamaotolaryngology/article-abstract/2606784 Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 30, 2023 12:00 PM Eastern Daylight Time

Video

HealthBeacon signs "very big deal" in key US market

HealthBeacon PLC

Contact Details Proactive Investors UK +44 20 7989 0813 uk@proactiveinvestors.com

May 30, 2023 11:02 AM Eastern Daylight Time

Video

NAVEX Announces AI-Powered Compliance Assistant

NAVEX Global

NAVEX, the leader in integrated risk and compliance management software, today announced NAVEX Compliance Assistant. The initial release of this new AI-powered functionality will offer instant answers to employee questions regarding company policies and procedures delivered in natural language. This functionality makes an organization’s compliance program more accessible and personal for all employees. As part of the NAVEX One GRC Information System, employees interact with NAVEX Compliance Assistant by asking it questions in their own words. The AI-powered Compliance Assistant then searches through a company’s policies and procedures to present a comprehensive answer to the employee’s inquiry. Compliance Assistant applies Large Language Model (LLM) technology to customer-controlled document sets for maximum relevance and accuracy. NAVEX’s secure cloud infrastructure protects document and data privacy. Rich NAVEX Integration Ensures Ease of Use and Data Security The AI-powered NAVEX Compliance Assistant is seamlessly integrated into NAVEX One People Hub, a unified, simplified way for employees to engage with the compliance program. Through People Hub, employees can conveniently report incidents, confirm policy adherence, complete training and disclose information within a user-friendly interface accessible on mobile devices. With the addition of Compliance Assistant, employees, and other authorized parties, can quickly clarify how to follow specific procedures and policies that apply to them. NAVEX Compliance Assistant offers a range of features tailored to meet the needs of organizations of all sizes, including: Intuitive chat interface: Employees can query the system with natural language questions about a policy or procedure of interest and receive prompt, accurate responses. Multilingual access: Users can ask questions and receive answers in 70 languages. Find relevant policies: Employees can easily search for and access relevant, verified policies and procedures, eliminating time-consuming manual searches or the need to reach out across departments to source an answer. Responsive access anywhere: NAVEX Compliance Assistant is accessible via the web and mobile devices, helping employees access critical compliance information from anywhere. Uncompromising privacy and security: NAVEX is committed to safeguarding all data within the systems it manages, including policy and procedure information and employee queries through Compliance Assistant. “Successful organizations turn governance, risk and compliance management into a competitive advantage. It helps prevent mistakes, motivate employees, and promotes confident decision-making,” said Sean Thompson, Chief Executive Officer at NAVEX. “In my years of experience with natural language user interface technology, incorporating it into a GRC program is one of the most exciting applications. Our new AI-enabled Compliance Assistant makes engaging with the compliance program simpler and more intuitive, which in turn makes employees more confident users of the system.” Expert point of view The adoption of AI-powered technologies to facilitate access to compliance-related information can bring great benefits. “Giving employees the ability to quickly and accurately access company policies and procedures fosters a culture of trust and safety with regards to risk mitigation. It also makes the whole process more efficient," said Darren Bradshaw, Chief Audit and Compliance Officer of Stellantis, a multinational automotive company on a journey of transformation into a sustainable mobility tech organization. Stellantis, as a customer of some NAVEX applications, plans to partner with the company to test the usability of this new application. To learn more about the AI-powered NAVEX Compliance Assistant, visit https://www.navex.com/en-us/products/navex-ethics-compliance/ai-employee-compliance-assistant/. Or, read our blog, “ Artificial Intelligence – The Next Frontier of GRC Management ” on Risk & Compliance Matters. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Scott Levesque +1 617-388-5773 scott.levesque@navex.com Company Website https://www.navex.com

May 30, 2023 08:30 AM Eastern Daylight Time

Image

American Diversified Holdings Corporation (OTC: ADHC) In Final Stage Development and Beta Testing of New ECommerce Platform Focused on CBD Products

American Diversified Holdings Corp.

American Diversified Holdings Corporation (OTC: ADHC) is announced today announce that the company is in the final stages of developing a state-of-the-art e-commerce site offering CBD products under ADHC brand UNIVERSAL WELLNESS. ADHC and its operating division UNIVERSAL WELLNESS previously announced a comprehensive alliance with GGII's leading group of a companies in the CBD and Hemp sector. ADHC's agreement with Green Globe Intl Group (OTC: GGII ), Hempaco (NASDAQ: HPCO ) and GGII's operating subsidiary Green Star Labs provides for a broad range of services and interrelated business activity. The GGII/HEMPACCO/GREENSTAR group has entered into this alliance with ADHC and will collaborate as outlined below: Formulation, manufacturing, private label, inventory management, packaging and shipment logistics with be provided by Green Star Labs under the Universal Wellness and Rolls Choice Brand. Jointly design a line of CDB, Dietary Supplements and Cosmetic products to be offered through ADHC' e-commerce beta platform. Introduce and negotiate endorsement agreements with social media influencers and noted HipHop/Rap luminaries. Hempacco currently has relationships deals with Snoop Dogg Brands, rap artist Rick Ross, Hemp Hop Smokables and Cheech and Chong, Hemp Cigarettes. Parties have agreed to a financial partnership including share issuances, line of credit for product inventory, capital formation and addition of future management. Parties have agreed to assess the develop of ADHC existing brand and future products under development, including products sold under the Rolls Choice Brand of cannabis adhesive pens and Universal Wellness lifestyle and CBD products. This alliance and new ECommerce business is set to springboard ADHC'S branded products into the rapidly growing CDB market sector. A recent report by Market Research Future (MRFR) indicated the CDB market is expected to reach over $59 billion by 2030 an 18% CAGR. See: Cannabidiol (CBD) Market Size Worth USD 59.3 Billion "The GGII/HPCO team is a great alliance partner for ADHC, we can now focus on pushing our brands to the forefront of the CBD and Cannabis markets with a manufacturing and brand building partner that is a dream come true for our shareholder," commented ADHC management. About Hempacco (NASDAQ: HPCO ) Hempacco Co., Inc.'s goal is Disrupting Tobacco's™ nearly $1 trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing herb, spice, and cannabinoid smokables and rolling paper. Hempacco owns The Real Stuff™ functional hemp cigarette and rolling paper brand. Hempacco's operating segments include: Manufacturing of smokables, hemp rolling paper, and cannabinoid sticks Smokable technology development The Real Stuff™ brand of functional smokables and rolling paper Cheech and Chong Hemp Cigarettes and Hemp Hop Smokables with Rick Ross Snoop Dogg Joint Venture of Hemp-Derived Products Learn more at www.hempacco.com. Order products at www.realstuffsmokables.com. About Green Globe International, Inc. (OTC: GGII ): Green Globe International is a Fast-Moving Consumer Goods incubator and holding company of intellectual property, products, and companies that better people's lives by helping them feel and look better inside and out. Green Globe International (GGII) owns or has interests in several brands and companies including; Green Star Labs, Inc., changing how people feel about themselves inside and out with nutritional supplements, CBD, and beauty products, and hemp CBD cigarette and rolling paper manufacturer Hempacco Co. Inc., (NASDAQ: HPCO) Disrupting Tobacco's™ $1 Trillion tobacco industry, with its subsidiaries and joint ventures including HempBox Vending, Inc. a vending and advertising company, Hempacco Paper Company, Inc., producing The Real Stuff Hemp Smokables and hemp paper smoking products like blunts, tubes, and cones, Cali Vibes, Inc. manufacturing cannabinoid cigarettes, HempHop Smokables, Inc., partnering with music producer and rapper Rick Ross, Cheech and Chong Smokables, Inc. delivering cannabinoid Hemp CBD cigarettes to consumers with Cheech and Chong as partners, StickIt USA, Inc., manufacturing a line of cannabinoid sticks, and HPDG, LLC a partnership with Snoop Dogg to develop hemp-derived consumer goods products. Green Globe International is publicly traded under the ticker symbol (OTC: GGII ). It continues to look for best-in-class companies, products, and patents to create Fast Moving Consumer Goods and channels to sell them, including retail automation and advertising platforms. ABOUT ADHC/UNIVERSAL WELLNESS ADHC is a publicly traded holding company trading under the ticker symbol (OTC: ADHC ). ADHC is currently developing two web-based branded businesses. Universal Wellness (UWS) is a wellness and lifestyle e-commerce site focused on providing innovative products, news, and the latest healthcare developments Shares Outstanding: 866 million Shares Restricted: 301 million Shares in the Float: 504 million Investor Contact: Andrew Birnbaum Chairman/CEO CEO@ADHCINVESTOR.com TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. Information contained herein includes forward-looking statements. SAFE HARBOR These statements relate to future events or future financial performance, involving known and unknown risks and uncertainties that may cause our actual results to be materially different to performance or achievements expressed. You should not place undue reliance on these statements, since they involve known and unknown risks. Any forward-looking statements reflect the current view with respect to future events and subject to uncertainties. Contact Details Andrew Birnbaum, Chairman/CEO CEO@ADHCINVESTOR.com

May 30, 2023 06:30 AM Eastern Daylight Time

Healthcare

RemSleep Holdings Inc. Provides a Corporate Update and Correction

Monogram Orthopaedics developing next generation surgical robot to enhance orthopaedic surgery

Being Overweight or Obese Increases Risk of Developing Colorectal Cancer

Immunic ultimately hoping to "offer patients a new kind of treatment" for multiple sclerosis

Neuronetics investing in NeuroStar awareness as drug-free treatment alternative for depression

William Shatner and HearingLife Team Up to Spread Awareness about the Importance of Hearing Care in the US

HealthBeacon signs "very big deal" in key US market

NAVEX Announces AI-Powered Compliance Assistant

American Diversified Holdings Corporation (OTC: ADHC) In Final Stage Development and Beta Testing of New ECommerce Platform Focused on CBD Products